Healthcare provider profile · identity verified

Barbara L Mann-Harbonic, MD

Family Practice · BERNVILLE, PA · NPI 1003894700

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	459	142
Levothyroxine Sodium	Levothyroxine Sodium	398	108
Lisinopril	Lisinopril	319	94
Omeprazole	Omeprazole	294	92
Losartan Potassium	Losartan Potassium	263	80
Metoprolol Succinate	Metoprolol Succinate	253	79
Amlodipine Besylate	Amlodipine Besylate	247	82
Simvastatin	Simvastatin	201	61
Methylprednisolone	Methylprednisolone	197	152
Metformin Hcl	Metformin Hcl	189	61
Hydrochlorothiazide	Hydrochlorothiazide	170	53
Rosuvastatin Calcium	Rosuvastatin Calcium	164	52
Sertraline Hcl	Sertraline Hcl	163	46
Metoprolol Tartrate	Metoprolol Tartrate	139	46
Furosemide	Furosemide	131	43
Glimepiride	Glimepiride	114	34
Pantoprazole Sodium	Pantoprazole Sodium	113	42
Azithromycin	Azithromycin	105	90
Gabapentin	Gabapentin	98	32
Eliquis	Apixaban	97	20
Tramadol Hcl	Tramadol Hcl	97	29
Albuterol Sulfate Hfa	Albuterol Sulfate	96	38
Metformin Hcl Er	Metformin Hcl	90	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	84	27
Famotidine	Famotidine	80	20
Mirtazapine	Mirtazapine	71	25
Potassium Chloride	Potassium Chloride	71	25
Escitalopram Oxalate	Escitalopram Oxalate	70	21
Synthroid	Levothyroxine Sodium	69	21
Alprazolam	Alprazolam	68	23
Trazodone Hcl	Trazodone Hcl	62	17
Fluticasone Propionate	Fluticasone Propionate	60	23
Montelukast Sodium	Montelukast Sodium	60	22
Doxycycline Hyclate	Doxycycline Hyclate	58	51
Trulicity	Dulaglutide	56	suppressed
Klor-Con M20	Potassium Chloride	51	17
Januvia	Sitagliptin Phosphate	49	14
Tamsulosin Hcl	Tamsulosin Hcl	48	21
Pravastatin Sodium	Pravastatin Sodium	47	15
Allopurinol	Allopurinol	45	15
Atenolol	Atenolol	45	14
Meloxicam	Meloxicam	44	19
Zolpidem Tartrate	Zolpidem Tartrate	41	11
Cephalexin	Cephalexin	39	31
Duloxetine Hcl	Duloxetine Hcl	38	12
Citalopram Hbr	Citalopram Hydrobromide	37	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	14
Paroxetine Hcl	Paroxetine Hcl	35	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	33	15
Solifenacin Succinate	Solifenacin Succinate	33	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	28	suppressed
Ezetimibe	Ezetimibe	26	suppressed
Hydralazine Hcl	Hydralazine Hcl	26	suppressed
Verapamil Er	Verapamil Hcl	26	suppressed
Bupropion Hcl Sr	Bupropion Hcl	25	suppressed
Carvedilol	Carvedilol	24	11
Clopidogrel	Clopidogrel Bisulfate	24	suppressed
Fluconazole	Fluconazole	24	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Lovastatin	Lovastatin	23	suppressed
Ozempic	Semaglutide	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	14
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Clonazepam	Clonazepam	22	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	22	20
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	22	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Oxycodone Hcl	Oxycodone Hcl	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	12
Lorazepam	Lorazepam	19	suppressed
Glipizide Er	Glipizide	18	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	14
Valsartan	Valsartan	17	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	16	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	11
Nebivolol Hcl	Nebivolol Hcl	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Midodrine Hcl	Midodrine Hcl	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Finasteride	Finasteride	13	suppressed
Linzess	Linaclotide	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	11
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Nystatin-Triamcinolone	Nystatin/Triamcinolone Acet	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Spironolactone	Spironolactone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error